From Dr. Fabio’s blog post:
Over the last few years, we have seen tremendous activity in the area of molecular imaging for prostate cancer. Just about every day we have colleagues asking about the various PET/CT imaging tests – what is available? How do they compare? What are the parameters for successful imaging?
We are proud to have contributed to this body of knowledge. Our work regarding C11-Acetate PET/CT imaging in the recurrent PCa setting with relationship to PSA kinetics has been recently published – representing the largest single-site evaluation of a molecular imaging agent. A link to the publication and brief overview of PET/CT Imaging for Prostate Cancer follow for your review. We hope you find this review useful.
Read the entire article on drfabio.com HERE
Prostate cancer–specific positron emission tomography (pcPET) has been shown to detect sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower than those levels detected by conventional imaging. Commonly used pcPET radiotracers in the setting of biochemical recurrence are reviewed including carbon 11/fludeoxyglucose 18 (F-18) choline, gallium 68/F-18 prostate-specific membrane antigen (PSMA), and F-18 fluciclovine.
Note that this article mentions C-11 acetate briefly but does not cover it. Phoenix Molecular Imaging is not shown on the map of imaging centers. Also, the study does not examine the significance of PSA doubling time, whereas it has been reported that short doubling time enhances detection with C11-Acetate even at very low PSA.
Read the entire article on sciencedirect.com HERE
PCF has updated it’s 2019 Patient Guide. Compiled with the contributions of top-tier doctors and researchers in prostate cancer, it is a must-have resource for patients and families. It focuses all of the information available about contemporary prostate cancer research, treatment, and lifestyle factors into one consolidated document.
Get it HERE.
As many as 40% of newly diagnosed PCa patients have unifocal disease, that is, just one focus of cancer. But that still leaves 60-80% of patients with multifocal PCa. Without evidence to the contrary, multiple foci in the same gland were thought to be biologically homogeneous, that is, identical to each other.
Then, along came the tools to analyze PCa at the molecular level, bringing new knowledge of the biology of PCa.
Read about this by clicking here.
If you experience a frequent urge to urinate—perhaps due to having an enlarged prostate if you’re a man, having given birth if you’re a woman, or having an “overactive bladder”—there may be a practical do-it-yourself solution to the problem, referred to as bladder training. It’s worth a try before resorting to medication or surgical procedures.
Read more at berkeleywellness.com HERE
Stereotactic body radiation therapy or SBRT (sometimes referred to as Cyberknife or SHARP) has had excellent 7-year outcomes in an update of the consortium study, including data from 10 single-institution trials and two multi-institutional trials. Get the details HERE.
Men who are initially diagnosed with intermediate-risk prostate cancer may or may not be good candidates for Active Surveillance. This excellent article begins to provide a basis for making that determination. You can read the article by clicking HERE.
Moderately hypofractionated IMRT (radiation therapy delivered in 20 to 26 treatments instead of the conventional 40-44 treatments) has received strong endorsement from all of the major US organizations of physicians who treat prostate cancer. Read more about this significant new guideline here.
So you’ve had your PSA test, and it came back high. Your doctor did a DRE and ran a few more tests, and assures you that prostate cancer is very unlikely. Still, you’re worried. What are some other causes of a high PSA?
Read about this in the Prostate Care Foundation blog HERE
The following presentation slides have some useful information with pros and cons of HDR and LDR Brachytherapy by Daniel Fernandez, MD, PhD. – Moffitt Cancer Center.
View or download the slides from HERE